KAKKIS EMIL D — SEC Form 4 filings
SEC reporting owner CIK 1248093. 9 Form 4 filings on record with FilingPulse; latest filed 2026-04-20.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-02-08 to 2026-04-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 7 filings — 242,838 shares, $9,773,264 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 73,434 shares @ $42.10 ($3,091,571) in Ultragenyx Pharmaceutical Inc., filed 2025-03-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | President & CEO, Director | 9 | — | 8 legs · 242,838 sh · $9,773,264 | 11 |
Form 4 filings — KAKKIS EMIL D
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-20 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 76,745 @ $0 · Grant/award (A): 132,693 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 71,177 @ $0 · Sale (S): 54,404 @ $22.80 | EDGAR |
| 2025-03-04 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 43,268 @ $0 · Grant/award (A): 107,292 @ $0 · Sale (S): 73,434 @ $42.10 · Sale (S): 25,000 @ $42.48 · Grant/award (A): 78,448 (derivative) @ $0 | EDGAR |
| 2024-12-31 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 11,727 @ $42.23 | EDGAR |
| 2024-12-11 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Gift (G): 20,000 @ $0 · Sale (S): 8,273 @ $50 | EDGAR |
| 2024-09-05 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 20,000 @ $55.85 | EDGAR |
| 2024-08-07 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 20,000 @ $50.17 | EDGAR |
| 2024-03-05 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 38,428 @ $0 · Tax withholding (F): 17,417 @ $53.69 · Grant/award (A): 3,132 @ $0 · Grant/award (A): 70,094 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 30,000 @ $45 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1248093 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →